Montelukast for persistent asthma.
D000085:Acetates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000191:economics; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage; D002648:Child; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D004311:Double-Blind Method; D004347:Drug Interactions; D005252:Fees, Pharmaceutical; D006801:Humans; D020024:Leukotriene Antagonists; D011804:Quinolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013440:Sulfides
D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D001507:Beclomethasone; C093875:montelukast